Randomized, controlled trial of transdermal clonidine for smoking cessation

Daniel E. Hilleman; Syed M. Mohiuddin; Michael G. Delcore; B. Daniel Lucas

doi:10.1177/106002809302700901

Randomized, controlled trial of transdermal clonidine for smoking cessation

Daniel E. Hilleman, Syed M. Mohiuddin, Michael G. Delcore, B. Daniel Lucas

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (

Original language	English (US)
Pages (from-to)	1025-1028
Number of pages	4
Journal	Annals of Pharmacotherapy
Volume	27
Issue number	9
DOIs	https://doi.org/10.1177/106002809302700901
State	Published - Sep 1993

All Science Journal Classification (ASJC) codes

Pharmacology (medical)

Access to Document

10.1177/106002809302700901

Fingerprint Dive into the research topics of 'Randomized, controlled trial of transdermal clonidine for smoking cessation'. Together they form a unique fingerprint.

Cite this

@article{826c54231e434c3c98fa6f43e83d0563,

title = "Randomized, controlled trial of transdermal clonidine for smoking cessation",

abstract = "OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (",

author = "Hilleman, {Daniel E.} and Mohiuddin, {Syed M.} and Delcore, {Michael G.} and Lucas, {B. Daniel}",

year = "1993",

month = sep,

doi = "10.1177/106002809302700901",

language = "English (US)",

volume = "27",

pages = "1025--1028",

journal = "Annals of Pharmacotherapy",

issn = "1060-0280",

publisher = "Harvey Whitney Books Company",

number = "9",

}

TY - JOUR

T1 - Randomized, controlled trial of transdermal clonidine for smoking cessation

AU - Hilleman, Daniel E.

AU - Mohiuddin, Syed M.

AU - Delcore, Michael G.

AU - Lucas, B. Daniel

PY - 1993/9

Y1 - 1993/9

N2 - OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (

AB - OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (

UR - http://www.scopus.com/inward/record.url?scp=0027429314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027429314&partnerID=8YFLogxK

U2 - 10.1177/106002809302700901

DO - 10.1177/106002809302700901

M3 - Article

C2 - 8219431

AN - SCOPUS:0027429314

VL - 27

SP - 1025

EP - 1028

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -

Randomized, controlled trial of transdermal clonidine for smoking cessation

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this